540 adults will have access to Dostarlimab (also called Jemperli and made by GSK). Dostarlimab is a monoclonal antibody and helps the immune system to fight cancer. It is given through a drip over 30 minutes in hospital.
Clinical trial evidence shows that with platinum-based chemotherapy it improves life expectancy and extends the time before the cancer gets worse. But because the study only collected data for a short time, the long-term benefits are uncertain. Dostarlimab has therefore been recommended for use in the Cancer Drugs Fund (CDF). This means that it will be available in the NHS to treat this type of womb cancer while further evidence is collected…
